Official registry condition

Relapsing-Remitting Multiple Sclerosis peptide trials

3 selected ClinicalTrials.gov records carrying the official condition label Relapsing-Remitting Multiple Sclerosis. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.

Registry records

3 selected records.

Connected peptides

1 profiles.

Registry update years

2015–2020 in selected records.

Indication intelligence

Selected evidence landscape

Connected profiles1

Exact peptide identities attached to retained registry observations carrying this condition label.

Trial phases2

Phase labels copied from the retained ClinicalTrials.gov versions.

Registry statuses1

Overall statuses at each retained observation, not necessarily current today.

Across the connected peptide profiles, PeptideScanner also carries 25 selected PubMed records and 11 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Relapsing-Remitting Multiple Sclerosis unless their own cited source says so.

Collection change ledger

Recently changed records on this condition hub

All recent changes →

These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.

Record added

ClinicalTrials.gov record NCT00203021

PeptideScanner retained ClinicalTrials.gov record NCT00203021 at 2026-11-16T17:42:50.457Z. Its registry update date was 2020-02-18, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 16, 2026
Cited source date
February 18, 2020
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00451451

PeptideScanner retained ClinicalTrials.gov record NCT00451451 at 2026-11-16T17:42:50.457Z. Its registry update date was 2015-01-26, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 16, 2026
Cited source date
January 26, 2015
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01874145

PeptideScanner retained ClinicalTrials.gov record NCT01874145 at 2026-11-16T17:42:50.457Z. Its registry update date was 2016-01-14, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 16, 2026
Cited source date
January 14, 2016
Evidence lane
Clinical trials

Attributed registry records

Selected records

All trial facets →